The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Get 7 days of access to industry updates through our news analysis and regulatory alerts
"*" indicates required fields